tiprankstipranks
Trending News
More News >
GlobeImmune (GBIM)
OTHER OTC:GBIM
US Market
Advertisement

GlobeImmune (GBIM) Price & Analysis

Compare
23 Followers

GBIM Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

11.43%88.57%
Insiders
11.43% Other Institutional Investors
88.57% Public Companies and
Individual Investors

GBIM FAQ

What was GlobeImmune’s price range in the past 12 months?
GlobeImmune lowest stock price was $0.05 and its highest was $0.05 in the past 12 months.
    What is GlobeImmune’s market cap?
    GlobeImmune’s market cap is $575.00.
      When is GlobeImmune’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were GlobeImmune’s earnings last quarter?
      Currently, no data Available
      Is GlobeImmune overvalued?
      According to Wall Street analysts GlobeImmune’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does GlobeImmune pay dividends?
        GlobeImmune does not currently pay dividends.
        What is GlobeImmune’s EPS estimate?
        GlobeImmune’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does GlobeImmune have?
        GlobeImmune has 5,752,000 shares outstanding.
          What happened to GlobeImmune’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of GlobeImmune?
          Currently, no hedge funds are holding shares in GBIM

          Company Description

          GlobeImmune

          GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
          Similar Stocks
          Company
          Price & Change
          Follow
          Biodexa Pharmaceuticals
          Processa Pharmaceuticals
          GRI Bio
          Ocean Biomedical
          Onconetix
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis